Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Molecular Immunology
|
December 1, 1995
Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2
S O Leung, D M Goldenberg, A S Dion, et al.
The Journal of Infectious Diseases
|
June 18, 2005
The effect of micronutrient supplementation on disease progression and death in simian immunodeficiency virus-infected juvenile male rhesus macaques
Barry R Goldin, Wenjun Li, Keith Mansfield, et al.
Cancer Research
|
December 1, 1995
Development and evaluation of the specificity of a rat monoclonal anti-idiotype antibody, WN, to an anti-B-cell lymphoma monoclonal antibody, LL2
M J Losman, S O Leung, L B Shih, et al.
The Journal of Antimicrobial Chemotherapy
|
March 21, 2009
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110
P Tebas, J Zhang, R Hafner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
September 28, 2005
Insulin resistance in HIV-infected men and women in the nutrition for healthy living cohort
Clara Y Jones, Ira B Wilson, Andrew S Greenberg, et al.
Cancer Research
|
December 1, 1995
Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody
M Juweid, R M Sharkey, A Markowitz, et al.
Cancer Research
|
December 1, 1995
Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies
R M Sharkey, M Juweid, J Shevitz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
May 29, 2007
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)
Pablo Tebas, Jiameng Zhang, Kevin Yarasheski, et al.
The American Journal of Medicine
|
May 1, 1992
Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic
J H Samet, H Libman, K A Steger, et al.
The Journal of Pediatrics
|
June 10, 2008
Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1
Tracie L Miller, E John Orav, Steven E Lipshultz, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Molecular Immunology
|
December 1, 1995
Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2
S O Leung, D M Goldenberg, A S Dion, et al.
The Journal of Infectious Diseases
|
June 18, 2005
The effect of micronutrient supplementation on disease progression and death in simian immunodeficiency virus-infected juvenile male rhesus macaques
Barry R Goldin, Wenjun Li, Keith Mansfield, et al.
Cancer Research
|
December 1, 1995
Development and evaluation of the specificity of a rat monoclonal anti-idiotype antibody, WN, to an anti-B-cell lymphoma monoclonal antibody, LL2
M J Losman, S O Leung, L B Shih, et al.
The Journal of Antimicrobial Chemotherapy
|
March 21, 2009
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110
P Tebas, J Zhang, R Hafner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
September 28, 2005
Insulin resistance in HIV-infected men and women in the nutrition for healthy living cohort
Clara Y Jones, Ira B Wilson, Andrew S Greenberg, et al.
Cancer Research
|
December 1, 1995
Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody
M Juweid, R M Sharkey, A Markowitz, et al.
Cancer Research
|
December 1, 1995
Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies
R M Sharkey, M Juweid, J Shevitz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
May 29, 2007
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)
Pablo Tebas, Jiameng Zhang, Kevin Yarasheski, et al.
The American Journal of Medicine
|
May 1, 1992
Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic
J H Samet, H Libman, K A Steger, et al.
The Journal of Pediatrics
|
June 10, 2008
Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1
Tracie L Miller, E John Orav, Steven E Lipshultz, et al.
Page
of 7